Availability (in Japan)
10 or more
(In Japan at 00:05,
Jan 16, 2026 in JST)
Size
100 µL (1 mg/mL)
| Data | |||||
|---|---|---|---|---|---|
| Clonality | Monoclonal | Clone | 10E9-2 | ||
| Isotype (Immunized Animal) | Mouse IgG2bκ | ||||
| Applications | |||||
| Immunogen (Antigen) | Recombinant C-terminal His-tagged hTERT protein of 157 amino acids of hTERT (position 304 to 460) | ||||
| Reactivity [Gene ID] | |||||
| Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | ||||
| Storage temp. | -20°C | Conjugate | Unlabeled | Manufacturer | MBL |
| Alternative names | TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, PFBMFT1 | ||||
| Background | Human telomerase reverse transcriptase (hTERT) is 1132 amino acids, 127 kDa protein, that is the catalytic subunit of the telomerase. Telomerase is an RNA-dependent DNA polymerase that catalyzes the addition of telomeric repeat unit, 5'-TTAGGG-3', to chromosome ends. Human telomerase consists of three major subunits: TERT, a template RNA called hTR, and telomerase-associated protein (TEP-1). hTERT and hTR are minimally required to reconstitute telomerase activity in vitro. In these subunits, hTR is constitutively expressed; TERT transcription is a primary mechanism for regulation of telomerase activity. In most human somatic cells, telomerase activity is undetectable, whereas approximately 85% of human cancers, including breast, prostate, stomach, bladder, colon, and liver cancer, have telomerase activity. Activation of telomerase is implicated in cell immortalization and cancer cell pathogenesis. | ||||
| Related products | M077-3 Mouse IgG2b (isotype control) |
||||
| Citations |
Western Blotting
ChIP
Immunoprecipitation
Immunocytochemistry
|
||||
| Product category |
|
||||